Remove Access Remove Clinical Trials Remove Events Remove Programs
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Adverse events were mostly mild and resolved spontaneously.

article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Cannabis Law Report

Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. The live webcast can be accessed here and on the investor page of Marinus’ website.

article thumbnail

Applied DNA Implements safeCircle™ COVID-19 Testing Program at Sarah Lawrence College

Cannabis Law Report

Mary Hartnett, Director of Medical Services at Sarah Lawrence College, stated, “safeCircle was our choice given the convenience of its on-site sample collection process, access to high-sensitivity RT-PCR-based testing with rapid turnaround times, ability to scale with our needs, and capacity to ease our administrative burdens.

article thumbnail

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

Cannabis Law Report

“At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. Mydecine has also successfully completed multiple acquisitions since its inception. For more information, please contact: Media Contacts.

article thumbnail

Press Release: Canada – Princeton mushroom research and development facility officially opens, sells first grow of psilocybin mushrooms

Cannabis Law Report

The grand opening event and reception invited investors, stakeholders and the residents of Princeton to take a tour through the facilities. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m The potential for psilocybin is untouched.”.

article thumbnail

Press Release: Maya and National Psychedelics Association Announce Partnership to Support Psilocybin-Assisted Services in Oregon

Cannabis Law Report

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.